Low-molecular-weight heparin (LMWH) is a class of anticoagulant medications.[1] They are used in the prevention of blood clots and, in the treatment of venous thromboembolism (deep vein thrombosis and pulmonary embolism), and the treatment of myocardial infarction.
Heparin is a naturally occurring polysaccharide that inhibits coagulation, leading to thrombosis. Natural heparin consists of molecular chains of varying lengths or molecular weights. Chains of varying molecular weights, from 5000 to over 40,000 daltons, make up polydisperse pharmaceutical-grade heparin.[2] LMWHs, in contrast, consist of only short chains of polysaccharides. LMWHs are defined as heparin salts having an average molecular weight of less than 8000 Da and for which at least 60% of all chains have a molecular weight less than 8000 Da. Various methods of fractionation or depolymerization of polymeric heparin obtain these.
Heparin derived from natural sources, mainly porcine intestine or bovine lung, can be administered therapeutically to prevent thrombosis. However, the effects of natural or unfractionated heparin are more unpredictable than LMWH.[3]
Because it can be given subcutaneously and does not require APTT monitoring, LMWH permits outpatient treatment of conditions such as deep vein thrombosis or pulmonary embolism that previously mandated inpatient hospitalization for unfractionated heparin administration.
Because LMWH has more predictable pharmacokinetics and anticoagulant effects, LMWH is recommended over unfractionated heparin for patients with massive pulmonary embolism[4] and for initial treatment of deep vein thrombosis.[5] As compared to placebo or no intervention, prophylactic treatment of hospitalized medical patients using LMWH and similar anticoagulants reduces the risk of venous thromboembolism, notably pulmonary embolism.[6][7]
More recently, these agents have been evaluated as anticoagulants in acute coronary syndrome (ACS) and managed by percutaneous intervention (PCI).[8][9]
The use of LMWH needs to be monitored closely in patients at extremes of weight or in patients with renal dysfunction. An anti-factor Xa activity may be useful for monitoring anticoagulation. Given its renal clearance, LMWH may not be feasible in patients with end-stage renal disease. LMWH can also be used to maintain the patency of cannulae and shunts in dialysis patients.
Patients with cancer are at higher risk of venous thromboembolism, and LMWHs are used to reduce this risk.[10] The CLOT study, published in 2003, showed that dalteparin was more effective in patients with malignancy and acute venous thromboembolism than warfarin in reducing the risk of recurrent embolic events.[11] The use of LMWH in cancer patients for at least the first 3 to 6 months of long-term treatment is recommended in numerous guidelines and is now regarded as a standard of care.[10]
The use of LMWHs should be avoided in patients with known allergies to LMWHs, heparin, sulfites or benzyl alcohol, in patients with active major bleeding, or in patients with a history of heparin-induced low blood platelet count (also known as heparin-induced thrombocytopenia or HIT). High treatment doses are contraindicated in acute bleeding such as cerebral or gastrointestinal hemorrhage. LMWHs depend more on renal function for their excretion than unfractionated heparin, so their biological half-life may be prolonged in patients with kidney failure. Therefore, their use in patients with creatinine clearance rate (CrCl) <30 mL/min may need to be avoided.[12] Apart from using unfractionated heparin instead, it may be possible to reduce the dose and/or monitor the anti-Xa activity to guide treatment.[3]
The most common side effects include bleeding, which could be severe or even fatal, allergic reactions, injection site reactions, and increases in liver enzyme tests, usually without symptoms.[13] Heparin and LMWHs can sometimes be complicated by a decrease in platelet count, a complication known as Heparin-induced thrombocytopenia.13 Two forms have been described: a clinically benign, non-immune and reversible form (Type I) and a rare, more serious immune-mediated form or Type II. HIT Type II is caused by the formation of autoantibodies that recognize complexes between heparin and platelet factor 4 (PF4) and is, therefore, associated with a substantial risk of thrombotic complications. The incidence is difficult to estimate but may reach up to 5% of patients treated with UFH or about 1% with LMWH.[13]
In clinical situations where the antithrombotic effect of LMWHs needs to be neutralized, protamine is used to neutralize heparin by binding to it.[9] Animal and in vitro studies have demonstrated that protamine neutralizes the antithrombin activity of LMWHs, normalizing the aPTT and thrombin time. However, protamine appears only partially to neutralize the anti-factor Xa activity of LMWH. Because the molecular weight of heparin impacts its interaction with protamine, the lack of complete neutralization of anti-factor Xa is likely due to reduced protamine binding to the LMWH moieties in the preparation. Protamine is a medicine that requires a high level of caution when used.
LMWH trials usually excluded individuals with unpredictable pharmacokinetics. As a result, patients with risks, such as the severely obese or in advanced stages of kidney failure, show decreased benefits due to fractionated heparin's increased half-life.[14] LMWHs should be used with extreme caution in patients undergoing any procedure involving spinal anesthesia/puncture, in conditions with increased risk of bleeding or in patients with a history of heparin-induced thrombocytopenia.
The coagulation cascade is a normal physiological process to prevent significant blood loss or hemorrhage following vascular injury. Unfortunately, there are times when a blood clot (thrombus) forms when it is not needed. For instance, some high-risk conditions, such as prolonged immobilization, surgery, or cancer, can increase the risk of developing a blood clot, which can potentially lead to significant consequences.
The coagulation cascade consists of a series of steps in which a protease cleaves and subsequently activates the next protease in the sequence.[2] Since each protease can activate several molecules of the next protease in the series, this biological cascade is amplified. The result of these reactions is to convert fibrinogen, a soluble protein, to insoluble threads of fibrin. Together with platelets, the fibrin threads form a stable blood clot.
Antithrombin (AT), a serine protease inhibitor, is the major plasma inhibitor of coagulation proteases.[15] LMWHs inhibit the coagulation process by binding to AT via a pentasaccharide sequence. This binding leads to a conformational change of AT, increasing the rate at which it inhibits activated factor X (factor Xa). Once dissociated, the LMWH is free to bind to another antithrombin molecule and subsequently inhibit more activated factor X. Unlike AT activated by heparin, AT activated by LMWH cannot inhibit thrombin (factor IIa) but can only inhibit clotting factor Xa.
The effects of LMWHs cannot be acceptably measured using the partial thromboplastin time (PTT) or activated clotting time (ACT) tests.[16] Instead, LMWH therapy is monitored by the anti-factor Xa assay, measuring anti-factor Xa activity rather than a clotting time. The methodology of an anti-factor Xa assay is that patient plasma is added to a known amount of excess recombinant factor X and excess antithrombin. If heparin or LMWH is present in the patient's plasma, it will bind to antithrombin and form a complex with factor X, inhibiting it from becoming factor Xa.[17] The amount of residual factor Xa is inversely proportional to the amount of heparin/LMWH in the plasma. The amount of residual factor Xa is detected by adding a chromogenic substrate that mimics the natural substrate of factor Xa, making residual factor Xa cleave it, releasing a colored compound that a spectrophotometer can detect.[17] Antithrombin deficiencies in the patient do not affect the assay because excess amounts of antithrombin is provided in the reaction.[17] Results are given in units/mL of anti-factor Xa, such that high values indicate high levels of anticoagulation and low values indicate low levels of anticoagulation in the plasma sample.[17]
LMWHs have a targeted therapeutic window of approximately 0.6–1.2 IU/ml. LMWH has a potency of 70 units/mg of anti-factor Xa activity and a ratio of anti-factor Xa activity to anti-thrombin activity of >1.5.[18] (see Table 1)
Table 1 Molecular weight (MW) data and anticoagulant activities of currently available LMWH products. Adapted from Gray E et al. 2008.[19]
Various methods of heparin depolymerization are used in the manufacture of low-molecular-weight heparin.[2] These are listed below:
Deaminative cleavage with nitrous acid forms an unnatural anhydromannose residue at the reducing terminal of the oligosaccharides produced. This can subsequently be converted to anhydromannitol using a suitable reducing agent, as shown in figure 1.
Likewise, chemical and enzymatic beta-elimination results in an unnatural unsaturated uronate residue (UA) at the non-reducing terminal, as shown in figure 2.
In addition, low molecular weight heparins can also be chemoenzymatically synthesized from simple disaccharides.[20]
Comparisons between LMWHs prepared by similar processes vary. For example, a comparison of dalteparin and nadroparin suggests they are more similar than products produced by different processes. However, a comparison of enoxaparin and tinzaparin shows they are very different from each other with respect to chemical, physical, and biological properties.
As might be expected, products prepared by distinctly different processes are dissimilar in physical, chemical, and biological properties.[2][15] Hence, a slight change in the depolymerization process could result in substantial variation in the structure or composition of a given LMWH.
Therefore, for every LMWH, a strictly defined depolymerization procedure is needed to guarantee the sameness of the final LMWH product and the predictability of clinical outcomes. LMWHs, as biological origin products, rely on stringent manufacturing procedures to guarantee the absence of biological or chemical contamination. It is, therefore, critical to adopt stringent manufacturing practices through rigorous quality assurance steps to ensure the highest quality of the produced LMWHs and to guarantee patient safety. These quality assurance steps, to be effective, need to be implemented from the raw material (crude heparin) collection to the final LMWH product.
Due to these identified and potential differences, several organizations, including the United States Food and Drug Administration, the European Medicines Agency, and the World Health Organization, regard LMWHs as individual products that should not be considered clinically equivalent, as they differ in many crucial aspects such as molecular, structural, physiochemical, and biological properties.[21][22][23] According to international guidelines, the choice of an individual LMWH should be based on its proven clinical safety and efficacy for each indication.[13] Therefore, switching from LMWH to another LMWH during treatment is not recommended during clinical practice.[24]
Differences from heparin (i.e. "unfractionated heparin") include:
When the commercial patent of LMWH expires, a generic or biosimilar LMWH can be marketed. The Food and Drug Administration approved the first "generic" LMWH in July 2010. The FDA has used five analytical and pharmacological criteria to establish the authenticity of a generic LMWH without requiring clinical studies in patients.[27]
From a regulatory viewpoint, the FDA considers LMWHs (as well as insulin, glucagon and somatropin) as "generic" drugs, even though they may be sourced from biological material. The European Medicines Agency considers LMWH biologicals, so their regulatory approval – as biosimilars – is approached differently than the FDA's.[28][29]
Den här artikeln har skapats av Lsjbot, ett program (en robot) för automatisk redigering. (2014-06)Artikeln kan innehålla fakta- eller språkfel, eller ett märkligt urval av fakta, källor eller bilder. Mallen kan avlägsnas efter en kontroll av innehållet (vidare information) Copernicia alba SystematikRikePlantaeDivisionTracheophytaKlassLiliopsidaOrdningArecalesFamiljArecaceaeSläkteCoperniciaArtCopernicia albaVetenskapligt namn§ Copernicia albaAuktorMorongSynonymer Coryphomia tectorum Ro…
Sanca coklat[1] Bothrochilus albertisii Klasifikasi ilmiah Kerajaan: Animalia Filum: Chordata Subfilum: Vertebrata Kelas: Reptilia Ordo: Squamata Subordo: Serpentes Famili: Pythonidae Genus: Bothrochilus Spesies: B. albertisii Nama binomial Bothrochilus albertisii(W. Peters & Doria, 1878) Sinonim Liasis Albertisii W. Peters & Doria, 1878 Leiopython gracilis Hubrecht, 1879 Liasis albertisii — Boulenger, 1893 Liasis fuscus albertisii — Stull, 1935 Liasis fuscus albertisi
ميتسورو أوغاتا (باليابانية: 小形満) معلومات شخصية الميلاد 24 مارس 1961 (العمر 62 سنة)محافظة آوموري مواطنة اليابان الطول 176 سنتيمتر[1] الوزن 68 كيلوغرام[1] الحياة العملية المدرسة الأم جامعة كاكوشوين المهنة مؤدي أصوات المواقع IMDB صفحته على IMDB تعديل مصدر
Paz de Olomouc El león checo, entre el símbolo de Matías Corvino (izda.) y el de Vladislao II (dcha.).Tipo de tratado bilateralFirmado 2 de abril de 1479OlomoucFirmantes Matías CorvinoVladislao II de BohemiaPartes Reino de Hungría y Reino de Bohemia[editar datos en Wikidata] La paz de Olomouc, también denominada tratado de Olomouc,[nota 1] fue firmada entre el rey de Hungría, Matías Corvino, y el rey de Bohemia, Vladislao II el 2 de abril de 1479 en Olomouc (Olmütz) y p…
Part of a series onTaxation An aspect of fiscal policy Policies Government revenue Property tax equalization Tax revenue Non-tax revenue Tax law Tax bracket Flat tax Tax threshold Exemption Credit Deduction Tax shift Tax cut Tax holiday Tax amnesty Tax advantage Tax incentive Tax reform Tax harmonization Tax competition Tax withholding Double taxation Representation Unions Medical savings account Economics General Theory Price effect Excess burden Tax incidence Laffer curve Optimal tax Theories …
Gereja Betlehem di Wamena, Papua Pegunungan Gereja Blenduk di Semarang, dibangun dalam arsitektur Eropa Protestanisme adalah salah satu dari enam agama resmi di Indonesia, yang lainnya adalah Islam, Katolik, Hindu, Buddha dan Konghucu. Ini meliputi seluruh Kekristenan di Indonesia, yang merupakan agama terbesar kedua di negara tersebut setelah Islam. Menurut statistik CIA pada 2010, 7% populasi Indonesia adalah Protestan.[1] Sensus nasional tahun 2018 mencatat 7,6% (20.246.267) [2 …
Природно-заповідний фонд Херсонської області станом на початок 2014 року налічує 79 об'єктів загальною площею 272 700,2 га[1]. Список об'єктів і територій Перелік територій та об'єктів природно-заповідного фонду загальнодержавного та місцевого значення Херсонської області с…
Artikel ini sebatang kara, artinya tidak ada artikel lain yang memiliki pranala balik ke halaman ini.Bantulah menambah pranala ke artikel ini dari artikel yang berhubungan atau coba peralatan pencari pranala.Tag ini diberikan pada Februari 2023. Tjakalsari adalah majalah yang pernah terbit dalam khasanah media massa dan Pers Indonesia di awal abad 20, sekitar tahun 1968.[1] Isinya bervariasi mulai soal filsafat, olahraga, profil tokoh, politik, dan lain-lain. Pada edisi edisi No. 2/Tahun…
United States historic placeNancy Ward TombU.S. National Register of Historic Places Nearest cityBenton, TennesseeCoordinates35°09′51″N 84°40′50″W / 35.16417°N 84.68056°W / 35.16417; -84.68056 (Ward, Nancy, Tomb)Area3 acres (1.2 ha)NRHP reference No.73001815[1]Added to NRHPApril 11, 1973 The Nancy Ward Tomb is the tomb of Nancy Ward, her brother and her son in Benton, Tennessee, U.S.[2] In 1923, a plaque reading Princess …
الارتحال في الأرجنتين. الارتحال (بالإنجليزية: Trekking) هو نشاط رياضي يتألف من المشي في البيئات الطبيعية ، وغالبا في التضاريس الجبلية الخلابة أو غيرها مع استخدام أبسط الوسائل المعيشية مثل النوم في خيمة صغيرة وأكل ما يعثر عليه المرء في طريقه من الغذاء إذا إنتهى رصيد غذائه.[1] ا…
هذه المقالة يتيمة إذ تصل إليها مقالات أخرى قليلة جدًا. فضلًا، ساعد بإضافة وصلة إليها في مقالات متعلقة بها. (يونيو 2019) باول أنطوان دوبويس معلومات شخصية الميلاد 7 ديسمبر 1795 باريس الوفاة 29 نوفمبر 1871 (75 سنة) [1] مواطنة فرنسا عضو في الأكاديمية الألمانية للعلوم لي…
2009 American filmThe Final InchPublicity posterDirected byIrene Taylor BrodskyProduced byIrene Taylor BrodskyTom GrantStarringMohammad Gulzar SaifiCinematographyJeff StreichIrene Taylor BrodskyEdited byBill WeberMusic byJoe JanigaCourtney Von DrehleProductioncompanyVermilion FilmsDistributed byHome Box OfficeRelease date April 1, 2009 (2009-04-01) Running time38 minutesCountryUnited StatesLanguagesEnglishUrduHindi The Final Inch is a short documentary about the effort to eradicat…
American film director and screenwriter Joel PotrykusJoel Potrykus at the 2012 Belfort Entrevues Film FestivalBornOssineke, Michigan, U.S.Occupation(s)Film director, screenwriterWebsitewww.joelpotrykus.com Joel Potrykus is an American film director and screenwriter. His feature film debut Ape won the Best New Director prize at the 2012 Locarno Film Festival,[1] while his follow-up feature Buzzard won the FIPRESCI Prize at the 2014 Ljubljana International Film Festival.[2] Early l…
Ini adalah nama Mandailing, marganya adalah Tanjung. H. Sukran Jamilan TanjungBupati Tapanuli TengahMasa jabatan23 Oktober 2014 – 10 Agustus 2016Penjabat hingga 17 Februari 2016PresidenJoko WidodoPendahuluRaja Bonaran SitumeangPenggantiBukit Tambunan (penjabat)Bakhtiar Ahmad SibaraniWakil Bupati Tapanuli TengahMasa jabatan17 Juli 2011 – 23 Oktober 2014PresidenSusilo Bambang YudhoyonoPendahuluEffendy PohanPenggantiDarwin Sitompul Informasi pribadiLahir4 Maret 1967 (umur&…
2015 EP by GFriendFlower BudEP by GFriendReleasedJuly 23, 2015 (2015-07-23)GenreK-popbubblegum popdance pophip hopLength19:36LabelSource MusicKT MusicGFriend chronology Season of Glass(2015) Flower Bud(2015) Snowflake(2016) Singles from Flower Bud Me Gustas TuReleased: July 23, 2015 Flower Bud is the second extended play (EP) by South Korean girl group GFriend. It was released by Source Music on July 23, 2015 and distributed by KT Music. The album contains four songs, incl…
19th century vigilante group in Montana Territory, USA Stuart's Stranglers was a well-known vigilante group in Montana that was founded in 1884 and led by Granville Stuart in response to widespread livestock theft at that time. They were also less commonly known as the Montana Stranglers. History Background Cattle thieves posed a significant threat to the profits of ranchers in Montana Territory. The rustlers operated well-organized networks that stole stock in one region and sold it in another,…
This article is an orphan, as no other articles link to it. Please introduce links to this page from related articles; try the Find link tool for suggestions. (January 2023) Nawabs Bugalow At Devda Gujarat Devda is a village in Porbandar district, Gujarat, India.[1] It is on the bank of the Minsar river. The population of the village is around 4000 and most of people are doing farming. And major resources of farming water is wells and tube wells and major crops are cotton, groundnut, oni…
«Good Company»Пісня Queenз альбому 'A Night at the Opera'Випущено 21 листопада 1975Номер треку 10Записано серпень-листопад 1975Жанр діксілендМова англійськаТривалість 3:26Лейбл EMIElektraАвтор слів Браян МейПродюсер «Queen»Рой Томас БейкерКомпозитор Браян Мей «Good Company» (укр. «Хороша компанія») — пі…
Pornography in Pakistan is subject to several legal provisions. The Government of Pakistan has placed ban on internet websites containing such material since November 2011. Major pornography website are already barred in Pakistan. In 2016, it was reported that government of Pakistan ordered Internet Service Providers (ISPs) in Pakistan to block more than 400,000 websites which contained pornographic content.[1] Later in 2019, around 800,000 additional website containing pornographic cont…
Paleolithic to Iron Age prehistory of France Part of a series on the History of France Ancient Prehistory Greek colonies 600 BC – 49 BC Celtic Gaul until 50 BC Roman Gaul 50 BC – 486 AD Middle Ages Francia and the Franks Merovingians 481–751 Carolingians 751–987 West Francia 843–987 Kingdom of France 987–1792 Direct Capetians 987–1328 Valois 1328–1498 Early modernAncien Régime Valois-Orl…
Lokasi Pengunjung: 13.58.26.236